{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:53Z","timestamp":1791331253100,"version":"4.3.1"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018289","name":"Shinnihon Foundation of Advanced Medical Treatment Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The magnitude of the natural killer (NK) cell response contributes to the achievement of treatment\u2010free remission (TFR) in patients with chronic myeloid leukemia (CML) and is regulated by the interaction between killer immunoglobulin\u2010like receptors (KIRs) on NK cells and human leukocyte antigen (HLA) class I molecules on target cells. The abundant combination between\n                    <jats:italic>KIR<\/jats:italic>\n                    and\n                    <jats:italic>HLA<\/jats:italic>\n                    through genetic polymorphisms determines the functional diversity of NK cells. We previously reported that\n                    <jats:italic>KIR3DL1\u2010HLA\u2010Bw<\/jats:italic>\n                    status is associated with achievement of TFR by reflecting NK cell potential. Patients with strong interaction between\n                    <jats:italic>KIR3DL1\/HLA\u2010Bw<\/jats:italic>\n                    were identified as having a higher molecular relapse risk, based on the \u201cmissing self\u201d hypothesis which suggests that the lack of cognate ligands for KIRs may induce target cell lysis. However, all the patients with strong interaction between\n                    <jats:italic>KIR3DL1\/HLA\u2010Bw<\/jats:italic>\n                    who received prior IFN\u2010\u03b1 therapy achieved TFR (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.007), explained by the \u201cNK cell licensing\u201d concept, whereby NK cells become more functional through the recognition \u201cself\u201d HLA class I molecules by KIRs. NK cell licensing may contribute to the potential efficacy of IFN\u2010\u03b1 treatment in patients with CML. We defined high\u2010risk molecular relapse patients and suggest that\n                    <jats:italic>KIR3DL1\/HLA\u2010Bw<\/jats:italic>\n                    status may help detect patients who could benefit from IFN\u2010\u03b1 for maintaining TFR.\n                  <\/jats:p>","DOI":"10.1002\/jha2.1053","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T12:40:03Z","timestamp":1732624803000},"page":"1278-1282","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["IFN\u2010\u03b1 treatment may enable discontinuation of TKIs in NK cell\u2010licensed patients with CML\u2010CP"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-3699","authenticated-orcid":false,"given":"Hiroshi","family":"Ureshino","sequence":"first","affiliation":[{"name":"Division of Hematology Respiratory Medicine and Oncology Department of Internal Medicine Faculty of Medicine Saga University  Saga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuharu","family":"Kamachi","sequence":"additional","affiliation":[{"name":"Division of Hematology Respiratory Medicine and Oncology Department of Internal Medicine Faculty of Medicine Saga University  Saga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kidoguchi","sequence":"additional","affiliation":[{"name":"Division of Hematology Respiratory Medicine and Oncology Department of Internal Medicine Faculty of Medicine Saga University  Saga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Hematology Respiratory Medicine and Oncology Department of Internal Medicine Faculty of Medicine Saga University  Saga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"e_1_2_12_1_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198687"},{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.165001"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100001"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(90)90097-S"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.5075"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195594"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03847"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-459545"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-303057"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00196-9"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30235-2"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng2035"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2341"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26550"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.1053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T07:49:19Z","timestamp":1734335359000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.1053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/jha2.1053"],"URL":"https:\/\/doi.org\/10.1002\/jha2.1053","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"2024-10-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}